

The Pivotal Role of Immune Functional Assays in Deciphering Immune Function Alterations

1 **Marion Debombourg^{1, 2}, Guy Oriol¹, Caroline Dupre¹, Chloé Albert-Vega¹, Fabienne Venet^{2,4},**
2 **Thomas Rimmelé^{3,5}, REALISM study group, Anne Conrad^{2,6,7}, Florence Ader^{2,6,8}, Vincent**
3 **Alcazer^{2,7}, VaccHemInf study group, Karen Brengel-Pesce¹, Aurore Fleurie¹, Sophie Trouillet-**
4 **Assant^{1, 2}, William Mouton^{1, 2,*}**

5 ¹ Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud
6 Hospital, Oullins-Pierre-Bénite, 69310, France.

7 ² International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, ENS
8 Lyon, Claude Bernard Lyon 1 University, Lyon, 69008, France.

9 ³ EA 7426 Pathophysiology of Injury □ Induced Immunosuppression, PI3, Claude Bernard Lyon 1
10 University □ bioMérieux □ Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437 Lyon, France.

11 ⁴ Immunology Laboratory, Hôpital Edouard Herriot, Hospices Civils de Lyon, 69437 Lyon, France.

12 ⁵ Anesthesia and Critical Care Medicine Department, Hôpital Edouard Herriot, Hospices Civils de
13 Lyon, 69437 Lyon, France.

14 ⁶ Infectious and Tropical Diseases Department, Hospices Civils de Lyon, Croix-Rousse Hospital,
15 Lyon, 69004, France.

16 ⁷ Clinical hematology department, Hospices Civils de Lyon, Lyon Sud Hospital, Oullins-Pierre-
17 Bénite, 69310, France.

18 ⁸ Claude Bernard Lyon I University, Villeurbanne, 69100, France.

19

20 *** Correspondence:**

21 William Mouton

22 william.mouton@chu-lyon.fr

23 **Keywords: Immune Dysfunction, Immune Functional Assay, Immune Monitoring Tool,**
24 **Transcriptomic Analysis, Method Comparison**

25

26 **1 Abstract**

27 Recently, immune function assessment has gained prominence in clinical settings. Immune
28 functional assays (IFAs), involving in vitro stimulation, offer a relevant approach to complement
29 traditional immunomonitoring methods which, while widely used, do not fully capture functional
30 immune capabilities. Despite growing interest in IFAs, their added value remains unclear.

31 To address this gap, our study aimed to determine if insights from IFAs could be replicated with
32 unstimulated immunoprofiling. Using the same analytical pipeline, we compared transcriptomic
33 profiles (Nanostring®) between stimulated (TruCulture®) and unstimulated (PaxGene™) samples
34 from i) patients with an overstimulated immune system 3-4 days post-sepsis onset, and ii) patients
35 undergoing immune reconstitution 6-months post-allogeneic hematopoietic stem cell transplantation
36 (allo-HSCT).

37 In sepsis, post-stimulation transcriptomic profiles revealed immune clusters linked to disease severity
38 and outcomes, surpassing traditional markers like mHLA-DR, while baseline analyses failed to
39 generate clinically relevant stratification. Similarly, allo-HSCT patients' post-stimulation data
40 revealed immune heterogeneity and treatment-related alterations not detected using baseline
41 transcriptomic or cellular profiles alone.

42 Our findings emphasize the value of IFAs in uncovering functional immune alterations that
43 unstimulated assessments may miss, which could offer deeper insights into immune dysfunction.
44 This study supports IFAs as complementary tools to current clinical practices, enhancing patient
45 management with a functional view of immune system dynamics.

46 2 Introduction

47 Over the past decade, the assessment of immune function has become a relevant approach for the
48 evaluation of host immune capacities (1–3) and immune reconstitution quality (4,5), as well as
49 disease monitoring (1,6,7) across various research domains and clinical contexts. In this regard,
50 Immune Functional Assays (IFA) have emerged as essential tools (1,8), composed by an *in vitro*
51 stimulation step followed by an analysis of the immune response induced by the stimulation, using a
52 varying degree of analytical complexity. These analyses can range from single cytokine secretion
53 measurement, such as interferon-gamma (9), to more intricate phenotyping techniques, such as
54 multiplex OMIC approaches (10). The employment of IFA, and more particularly TruCulture[®] tubes
55 (Myriad RBM, Austin, USA) combined with Nanostring[®] technology to quantify mRNA gene
56 expression level, allowed us to obtain valuable insights into two distinct immunocompromised
57 populations. In the setting of sepsis, transcriptomic data post-staphylococcal enterotoxin B (SEB)
58 stimulation in TruCulture[®] tubes enabled us to stratify a sepsis population according to severity and
59 proved to be more effective than measurements of mHLA-DR, a marker classically used for immune
60 monitoring (11). In the case of allogenic hematopoietic stem cell transplantation (allo-HSCT), gene
61 expression observed post-SEB and post-lipopolysaccharide (LPS) stimulation allowed to identify
62 immune functional alterations associated with ongoing immunosuppressive treatment at 6 months
63 post-transplantation, which could not be revealed solely through cell count analyses, even though
64 they are considered as reference markers for immune reconstitution (4).

65 Other studies have also highlighted the advantages of employing IFA over traditionally used
66 immunomonitoring tools, such as peripheral white blood cell count or immune cell phenotyping
67 conducted without any *in vitro* stimulation step (12–14). But to date, and to our knowledge, no study
68 has addressed the question of whether a stimulation step is necessary for obtaining information that
69 could enhance the detection of functional immune alterations. Furthermore, direct comparisons
70 between stimulated and unstimulated samples using analytical pipelines differing only on the *in vitro*
71 stimulation step have not been performed, thereby hindering a clear demonstration of the added value
72 of IFA.

73 In this study, we aimed to address this gap by conducting two independent assessments of the added
74 value of *in vitro* stimulation compared to baseline transcriptomic profiles for revealing immune
75 function alterations, in the previously mentioned clinical settings: sepsis progression and immune
76 reconstitution following allo-HSCT.

77 3 Material & Methods

78 3.1 Study population

79 *Sepsis cohort* - Patients with sepsis were included in the REALISM study (NCT02638779), a
80 prospective longitudinal, single-center observational study, conducted in the anesthesiology and
81 intensive care department of the Edouard Herriot hospital between December 2015 and June 2018
82 (*Hospices Civils de Lyon*, HCL, Lyon, France). Blood sampling was performed 3 to 4 days after
83 septic shock onset. The study protocol was approved by the regional ethics committee (*Comité de*
84 *Protection des Personnes Sud-Est II*, number 2015–42-2).

85 *Allo-HSCT cohort* - Allo-HSCT recipients were included in the prospective, single-center cohort
86 study “VaccHemInf” (NCT03659773) between May 2018 and August 2020 at a median time of 6
87 months post-transplantation at the hematology department of the Lyon university hospital (HCL,

88 France). The study protocol was approved by the regional ethics committee (*Comité de Protection*
89 *des Personnes Sud-Est V*, Grenoble, France, number 69HCL17_0769).

90 For each study, blood samples from 10 healthy volunteers (HVs) were concomitantly obtained from
91 the national blood service (*Etablissement Français du Sang*), following the regulatory authorizations
92 for the handling and conservation of these samples from the regional ethics committee (*Comité de*
93 *Protection des Personnes Sud-Est II*) and the French ministry of research (*Ministère de*
94 *l'Enseignement supérieur, de la Recherche et de l'Innovation*, DC-2008–64).

95 Written informed consent was obtained from each healthy donor and from the patients or their
96 relatives upon inclusion in these studies.

97 **3.2 Sample collection**

98 For each study, at the time of sampling, heparinized-whole blood was collected and incubated in
99 TruCulture[®] tubes (Myriad Rbm, Austin, TX, USA) pre-filled with either LPS or SEB, as previously
100 described (4,11). Unstimulated whole blood samples were also collected in PaxGene[™] Blood RNA
101 tubes (PreAnalytiX/QIAGEN Inc., Valencia CA, USA) and stored at -80°C.

102 **3.3 Isolation of RNA from PaxGene whole-blood**

103 Total RNA was extracted from whole-blood samples using the PaxGene[™] Blood RNA Kit
104 (PreAnalytiX/QIAGEN Inc., Valencia CA, USA). After thawing, blood RNA tubes were centrifuged
105 at 3,000g for 10 min at room temperature (RT). The supernatant was decanted, followed by the
106 addition of 4 ml RNase-free water and redissolving of the pellet. Next, the tube was centrifuged again
107 at 3,000 g for 10 min at RT, and the supernatant was discarded. The pellet was resuspended in 350 µl
108 of buffer BR1 and transferred to a microcentrifuge tube. Next, 300 µl of buffer BR2 and 40 µl of
109 proteinase K were added, mixed, and incubated for 10 min at 55°C using a shaker-incubator at 450
110 rpm. This lysate was transferred to a PaxGene shredder (Qiagen, Valencia, CA) spin column and
111 centrifuged at 20,000 g for 3 min at RT. The supernatant of the flow-through fraction was transferred
112 to a fresh microcentrifuge tube, and 350 µl of 100% ethanol was added and mixed. Then 700 µl of
113 this sample was transferred to a PaxGene RNA spin column and centrifuged at 10,000g for 1 min at
114 RT. The flow-through was discarded, and this step was repeated with the remaining sample from the
115 previous step.

116 Next, 350 µl of buffer BR3 was added onto the RNA spin column, which was centrifuged at 10,000g
117 for 1 min at RT. The flow-through was discarded, and 10 µL of DNase 1 was mixed with 70 µl of
118 buffer RDD in a separate tube. This was pipetted onto the spin column membrane and incubated at
119 20–30°C for 15 min. Then 350 µl of buffer BR3 was added onto the RNA spin column, which was
120 centrifuged at 10,000 g for 1 min at RT. The flow-through was then discarded. Next, 500 µl of buffer
121 BR4 was added onto the RNA spin column, which was centrifuged at 10,000 g for 1 min at RT. The
122 flow-through was discarded, and 500 µl of buffer BR4 was added again onto the RNA spin column
123 and centrifuged at 10,000 g for 3 min at RT. The flow-through was discarded. The RNA spin column
124 was transferred to a 1.5-ml microcentrifuge tube, and 40 µl of buffer BR5 was pipetted onto the
125 column to elute the membrane-bound RNA. The column was then centrifuged at 10,000 g for 1 min
126 at RT. This step was repeated with the same 40-µl buffer BR5, and the eluate was incubated at 65°C
127 for 5 min, then chilled on ice. RNA concentration was estimated using the Nanodrop One
128 spectrophotometer (Thermo Scientific, Swedesboro, NJ) according to the manufacturer's instruction.

129 **3.4 Gene expression analysis**

130 Gene expression was evaluated through a 89- (11) and 144-gene panel (4) using the NanoString®
131 technology for the sepsis and allo-HSCT study, respectively. Briefly, 300 ng of RNA were
132 hybridized to the probes at 67 °C for 18 h using a thermocycler (Biometra, Tprofessional TRIO,
133 Analytik Jena AG, Jena, Germany). After removal of excessive probes, samples were loaded into the
134 nCounter Prep Station (NanoString® Technologies, Seattle, WA, USA) for purification and
135 immobilization onto the internal surface of a sample cartridge for 2–3 h. The sample cartridge was
136 then transferred and imaged on the nCounter Digital Analyzer (NanoString® Technologies) where
137 color codes were counted and tabulated for each panel of genes. Data treatment and normalization
138 were performed on nSolver® analysis software (version 4.0, NanoString® Technology) using internal
139 controls and 3 housekeeping genes (detailed in **Table S1 and S2**). Of note, for both cohorts, analyses
140 were conducted using genes with expressions exceeding the background noise threshold in more than
141 75% of individuals, as previously described (4,11).

142 **3.5 Statistical Analysis**

143 Normality testing was performed using the Shapiro-Wilk normality test. The distribution of
144 quantitative data was expressed as mean (range) or median (interquartile range, [IQR]) where
145 appropriate. Cluster analyses were performed using the PAM method with correlation and average
146 distance, as previously described by Albert-Vega et al. (11). The alluvial plot was obtained via
147 <http://www.bioinformatics.com.cn>, a free online platform for data analysis and visualization.
148 Principal component analysis (PCA) was carried out using Partek Genomics Suite software (version
149 7.0; Partek Inc., St. Louis, MO), and Euclidean distances were calculated as previously described by
150 Mouton et al. (4). Differences in Euclidean distances between groups were calculated using a non-
151 parametric unpaired Wilcoxon test with Benjamini correction. Differences in standard deviations
152 (SD) were calculated using paired Pitman-Morgan test. Statistical analyses were conducted using
153 GraphPad Prism software (version 8; GraphPad software, La Jolla, CA, USA) and R (version R.2.2).
154 *P* values and adjusted *P* values (*P* adj) < 0.05 were considered significant.

155 **4 Results**

156 **4.1 Immune function assessment appears as an essential tool to obtain clinically relevant** 157 **clustering in the context of sepsis**

158 Overall, 28 out of the 30 patients with sepsis as well as 10 HVs initially included in the Albert-Vega
159 et al. study were analyzed herein, as 2 unstimulated samples had not been collected. Among these
160 patients, 7 developed a hospital-acquired infection (HAI) during ICU stay, and 3 had died at day 28
161 (**Table S3**). Following the data control and normalization steps described above, 81 out of 86 genes
162 initially analyzed were kept for analyses through PaxGene™ tubes. To evaluate the added value of
163 the stimulation in identifying immune functional alterations in a sepsis population, statistical analyses
164 and clustering must be conducted using an equal number of patients and genes, whose expression
165 was measured post-stimulation or from PaxGene™ tubes without stimulation. To that end, we first
166 aimed to validate that the conclusions derived from the restricted post-stimulation dataset were
167 consistent with those obtained from the complete dataset published in the Albert-Vega et al. study.

168 We thus conducted again the multivariate clustering analysis from gene expression levels post-SEB
169 stimulation using 81 genes, 28 patients with sepsis, and 10 HVs. The analysis found 3 clusters with
170 the same composition as previously described by Albert-Vega et al. (**Figure 1 left, Table S4**). The
171 first cluster (n=11) grouped together all the HVs and one patient with sepsis, constituting the
172 healthier cluster, gathering immunocompetent individuals. The second cluster (n=13) included all
173 non-survivors, hence designated as the severe cluster. It was characterized by a diminished immune

174 responsiveness upon *in vitro* SEB stimulation and a specific modulation of genes previously
175 described to be associated with mortality, such as MDC1 and IFIT44L. The third cluster (n=14)
176 included 86% (6/7) of the patients with sepsis who developed a HAI, forming the intermediate
177 cluster. As demonstrated by Albert-Vega et al., these patients exhibited, among other, an
178 upregulation of the HLA family and interferon-related genes, suggesting a potential for immune
179 recovery, implying that patients identified in this cluster may benefit from immunostimulatory
180 therapy.

181 Having confirmed the consistency of the conclusions that can be drawn from the restricted dataset,
182 we conducted the same analyses on PaxGene™ tubes (**Figure S1.A**). Using the dataset obtained from
183 PaxGene™ tubes, we identified an equivalent of the healthier cluster comprising all HVs, consistent
184 with observations from the post-stimulation gene dataset. However, in the absence of stimulation,
185 this healthier cluster included 4 of 9 patients with sepsis who had been classified within the severe
186 cluster identified post-SEB stimulation, including patients who exhibited an evident and profound
187 alteration of immune function post-stimulation (**Figure 1 right**). This discrepancy demonstrates the
188 loss of ability to distinguish immunocompetent individuals among a sepsis population based on gene
189 expression analysis from unstimulated whole blood.

190 Altogether, these results highlight a notable discrepancy in patient stratification according to immune
191 alteration profiles when determined with or without *in vitro* stimulation, and suggest that, during the
192 course of sepsis, immune function assessment can reveal distinct immune profiles that are coherent
193 with clinical characteristics.

194 **4.2 Immune function assessment remains necessary in the context of allo-HSCT to uncover** 195 **immune function alterations**

196 We then evaluated the added value of the stimulation to reveal immune functional alterations in
197 another clinical context, e.g. during the immune reconstitution after allo-HSCT. For this study, 59 of
198 the 60 allo-HSCT recipients and 5 of the 10 HVs initially included were analyzed, as one patient
199 sample did not pass quality control, and no PaxGene™ tubes were available for 5 HVs. Regarding
200 the hematological- and transplant-related characteristics of allo-HSCT recipients included at a
201 median [IQR] of 6.5 [5.8-8.3] months after transplantation, 52.5% had been transplanted due to acute
202 myeloid leukemia, 35.6% had active graft-versus-host disease (GvHD) at inclusion, and 32.2% were
203 undergoing immunosuppressive treatment at inclusion (**Table S5**).

204 Following the data control and normalization steps, 121 out of 138 and 134 genes initially analyzed
205 post-SEB and -LPS stimulation, respectively, were kept for analyses through PaxGene™ tubes. As
206 for the sepsis study, we first aimed to confirm whether the same conclusions obtained from the entire
207 post-stimulation transcriptomic dataset used in the Mouton et al. study could be replicated using the
208 new restricted dataset.

209 We thus conducted again the PCA from gene expression levels post-stimulation with either LPS or
210 SEB using 121 genes, 59 allo-HSCT recipients, and 5 HVs. Similarly, post-stimulation gene
211 expression analysis revealed a strong homogeneity among HVs, while allo-HSCT recipients
212 represented a more heterogeneous population (**Figure S2**). For quantitative purposes, we once again
213 calculated, using the PCA projection from the restricted dataset, the Euclidean distance of each allo-
214 HSCT recipient to the centroid of the HV population, which serves as a reference value for a
215 functional immune response. We hypothesized that a greater distance corresponds to a more impaired
216 immune response and assessed the association between these distances and clinical data. Thus, using
217 this restricted post-stimulation dataset, we were able to confirm an increase in Euclidean distance

218 associated with an ongoing immunosuppressive treatment (median [IQR] 9.71 [4.91-12.6] versus
219 13.77 [11.34-18.43] $P_{adj} < 0.047$, **Table S6**) (4).

220 We then proceeded to conduct the same analyses on PaxGene™ tubes (**Figure S1.B**). Whether
221 obtained post-stimulation or under unstimulated conditions, the immune profiles projected onto the
222 first 2 principal components of the PCA revealed similar overall variability, explaining 36.6% and
223 36.7% of the overall variance, respectively (**Figure 2.A**). Nevertheless, as illustrated in the PCA
224 overlay, the immune functional heterogeneity of allo-HSCT recipients, captured using gene
225 expression analysis through unstimulated whole blood, was less pronounced. This was supported by
226 two indicators, the inertia of the point cloud formed by the allo-HSCT immune profiles and the SD of
227 the Euclidean distance (**Figure 2.B**), which were both highly reduced in the unstimulated condition
228 compared to the stimulated one (inertia: 39.4 vs. 87.5 and SD: 3.814 vs. 6.977, p-value <0.001). In
229 addition, neither ongoing immunosuppressive treatment (**Figure 2.C**) nor any other parameter (**Table**
230 **S7**) could account for the significant increase in the Euclidean distance using the gene expression
231 dataset obtained without whole blood stimulation, in contrast to that obtained post stimulation. It
232 appears that in the context of allo-HSCT, immune function assessment through IFA uncovers a
233 treatment-dependent immune response, which could help improve the monitoring of post-
234 transplantation immune reconstitution by complementing the classical markers currently used.

235 **5 Discussion**

236 In this study, we aim to evaluate the added value of IFA in capturing altered immune function
237 compared to unstimulated assays in two distinct clinical contexts. To do so, we compared
238 transcriptomic data obtained after a non-specific whole-blood stimulation in TruCulture® with those
239 acquired using PaxGene samples, employing the same analytical pipeline.

240 In the first context of sepsis immune monitoring, several basal-state biomarkers, i.e., without
241 stimulation step, are routinely used in clinical practice, such as mHLA-DR, CD4⁺/CD8⁺ ratio, and
242 circulating IL-10 (15). Indeed, persistent low mHLA-DR expression (16–18), decrease in
243 CD4⁺/CD8⁺ ratio (19–22) as well as an increase circulation in IL-10 (23) have been reported to
244 predict mortality in septic shock. Several studies have already employed IFA to assess functional
245 immunity in this context; as Antonakos et al. who demonstrated that TNF- α production post-LPS
246 stimulation on day 3 post-sepsis onset could discriminate patients with sepsis from healthy control
247 subjects (24), or Mazer et al. who used IFN- γ and TNF- α ELISpot assays post-anti-CD3/anti-CD28
248 antibodies and LPS stimulation, respectively, to depict early, profound and sustained suppression of
249 functional immunity in deceased patients (25). Despite the interest in IFA for assessing immune
250 function, no study has yet clearly assessed the added value of stimulation compared to basal-state
251 biomarkers in depicting immune alterations. Therefore, using the same analytical pipeline employed
252 by Albert-Vega et al. (11), which demonstrated relevant stratification based on immune functional
253 profiles during the course of sepsis, we evaluated whether the dataset obtained from unstimulated
254 PaxGene samples collected from the same patients at the same visit could reveal similar results. We
255 observed that the unstimulated dataset did not yield clinically relevant clusters, underscoring the
256 value of stimulation in revealing distinct immune profiles during sepsis.

257 Moreover, our results align with the previous observation made by Albert-Vega et al., showing that
258 patients' stratification according to post-SEB stimulation transcriptomic profiles was more effective
259 than using the commonly employed mHLA-DR marker to underline the heterogeneity in sepsis. This
260 reinforces the relevance of IFA employment in this setting, as also suggested by Wang et al. (6).

261 In the second context of allo-HSCT, immune cell counts such as TCD4⁺ cell count and CD4⁺/CD8⁺
262 ratio are classically quantified to monitor immune reconstitution post-transplant (26,27). However,
263 despite their widespread clinical use, these approaches provide no information regarding the
264 qualitative characteristics of this immune reconstitution (14,28). In this regard, IFA have
265 demonstrated complementary value to these classically used methods. Gjaerde et al. conducted
266 proteomic analysis following whole-blood stimulation in TruCulture®, revealing heterogeneity in
267 cytokine production among patients and identifying a cluster with reduced responses, suggesting
268 possible functional immune deficiency (5). Similarly, Mouton et al. used non-specific TruCulture®
269 stimulation coupled with a transcriptomic approach to capture a broad range of immune profiles,
270 identifying altered immune functional profiles associated with ongoing immunosuppressive treatment
271 (4). As for the sepsis context, we aimed to distinctly evaluate the added-value of IFA compared to
272 basal-state biomarkers in deciphering immune alterations. To do so, using the same analytical
273 pipeline as Mouton et al., we analyzed unstimulated PaxGene sample collected from the same
274 patients at the same visit. In comparison with the results obtained post *in vitro* stimulation, the use of
275 unstimulated dataset failed to detect any functional alterations, resulting in homogeneous
276 transcriptomic immune profiles among patients. These profiles were not associated with any clinical
277 event or characteristic, especially with the use of immunosuppressive treatments, contrasting with the
278 findings observed post-stimulation. Once again, these results were in line with conclusion made by
279 Mouton et al., which underlined that a clustering approach post-stimulation using transcriptomic data
280 is more effective than solely analyzing cell counts in revealing the heterogeneity of immune profiles
281 during post-transplant reconstitution. This supports the relevance of IFA, as also suggested by Naik
282 et al. (14).

283 However, this study has limitations that need to be addressed. Studies with larger sample sizes will
284 be essential to fully evaluate the clinical utility of IFAs and their potential benefits for patient care.
285 Here, we used previously established bioinformatics pipelines specifically designed for post-
286 stimulation data to enable a precise comparison; however, we acknowledge that alternative methods
287 may be more suitable for unstimulated datasets. Finally, studies incorporating longitudinal follow-
288 ups of immunocompromised patients at various stages of their conditions would be of interest.

289 Overall, the present analyses showed that the conclusions obtained through a clustering-based
290 stratification of post-stimulation data, in two different clinical contexts could not be replicated using
291 unstimulated samples. We reinforce the interest of IFA as complementary tool to traditional
292 immunomonitoring methods, as already well demonstrated for specific immunity in infectious
293 contexts, such as SARS-CoV-2 (29) or *Mycobacterium tuberculosis* (30). The design of the present
294 study highlighted, for the first time, the added value of the stimulation step in identifying functional
295 immune alterations. This observation could pave the way for, or at least encourage, the broader
296 implementation of IFA as a complementary tool in immunomonitoring.

297

298 **6 Reference**

- 299 1. Müller S, Kröger C, Schultze JL, Aschenbrenner AC. Whole blood stimulation as a tool for
300 studying the human immune system. *Eur J Immunol* (2023) doi: 10.1002/eji.202350519
- 301 2. Urrutia A, Duffy D, Rouilly V, Posseme C, Djebali R, Illanes G, Libri V, Albaud B, Gentien D,
302 Piasecka B, et al. Standardized Whole-Blood Transcriptional Profiling Enables the

- 303 Deconvolution of Complex Induced Immune Responses. *Cell Reports* (2016) 16:2777–2791.
304 doi: 10.1016/j.celrep.2016.08.011
- 305 3. Barateau V, Peyrot L, Saade C, Pozzetto B, Brengel-Pesce K, Elsensohn M-H, Allatif O,
306 Guibert N, Compagnon C, Mariano N, et al. Prior SARS-CoV-2 infection enhances and
307 reshapes spike protein-specific memory induced by vaccination. *Science Translational*
308 *Medicine* (2023) 15: doi: 10.1126/scitranslmed.ade0550
- 309 4. Mouton W, Conrad A, Alcazer V, Boccard M, Bodinier M, Oriol G, Subtil F, Labussière-Wallet
310 H, Ducastelle-Lepretre S, Barraco F, et al. Distinct Immune Reconstitution Profiles Captured by
311 Immune Functional Assays at 6 Months Post Allogeneic Hematopoietic Stem Cell
312 Transplantation. *Transplantation and Cellular Therapy* (2023) 29: doi:
313 10.1016/j.jtct.2022.10.025
- 314 5. Gjørde LK, Brooks PT, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Nielsen SD,
315 Ostrowski SR, Sengeløv H. Functional immune reconstitution early after allogeneic
316 haematopoietic cell transplantation: A comparison of pre- and post-transplantation cytokine
317 responses in stimulated whole blood. *Scandinavian Journal of Immunology* (2021) 94: doi:
318 10.1111/sji.13042
- 319 6. Wang Y, Gloss B, Tang B, Dervish S, Santner-Nanan B, Whitehead C, Masters K, Skarratt K,
320 Teoh S, Schibeci S, et al. Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic
321 Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups
322 With Differential Responses to Immunostimulant Drugs. *Frontiers in Immunology* (2021) 12:
323 <https://www.frontiersin.org/articles/10.3389/fimmu.2021.634127> [Accessed January 30, 2024]
- 324 7. Svanberg R, MacPherson C, Zucco A, Agius R, Faitova T, Andersen MA, da Cunha-Bang C,
325 Gjørde LK, Møller MEE, Brooks PT, et al. Early stimulated immune responses predict clinical
326 disease severity in hospitalized COVID-19 patients. *Commun Med* (2022) 2:1–15. doi:
327 10.1038/s43856-022-00178-5
- 328 8. Albert-Vega C, Tawfik DM, Trouillet-Assant S, Vachot L, Mallet F, Textoris J. Immune
329 Functional Assays, From Custom to Standardized Tests for Precision Medicine. *Front Immunol*
330 (2018) 9:2367. doi: 10.3389/fimmu.2018.02367
- 331 9. Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of
332 tuberculosis infection, differentiating from active tuberculosis, and decision making for
333 initiating treatment or preventive therapy of tuberculosis infection. *International Journal of*
334 *Infectious Diseases* (2022) 124:S12–S19. doi: 10.1016/j.ijid.2022.02.047
- 335 10. Saint-André V, Charbit B, Biton A, Rouilly V, Possémé C, Bertrand A, Rotival M, Bergstedt J,
336 Patin E, Albert ML, et al. Smoking changes adaptive immunity with persistent effects. *Nature*
337 (2024) 626:827–835. doi: 10.1038/s41586-023-06968-8
- 338 11. Albert Vega C, Oriol G, Bartolo F, Lopez J, Pachot A, Rimmelé T, Venet F, Leray V, Monneret
339 G, Delwarde B, et al. Deciphering heterogeneity of septic shock patients using immune
340 functional assays: a proof of concept study. *Sci Rep* (2020) 10: doi: 10.1038/s41598-020-73014-
341 2

- 342 12. Haem Rahimi M, Venet F, Lukaszewicz A-C, Peronnet E, Cerrato E, Rimmelé T, Monneret G.
343 Interferon-Gamma-Release assay and absolute CD8 lymphocyte count for acquired
344 immunosuppression monitoring in critically ill patients. *Cytokine* (2024) 174: doi:
345 10.1016/j.cyto.2023.156474
- 346 13. Van Den Brink MRM, Velardi E, Perales M-A. Immune reconstitution following stem cell
347 transplantation. *Hematology* (2015) 2015:215–219. doi: 10.1182/asheducation-2015.1.215
- 348 14. Naik S, Vasileiou S, Aguayo-Hiraldo P, Mukhi S, Sasa G, Martinez C, Krance RA, Gottschalk
349 S, Leen A. Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant
350 Recipients. *Biology of Blood and Marrow Transplantation* (2020) 26:911–919. doi:
351 10.1016/j.bbmt.2020.01.005
- 352 15. Yao R-Q, Ren C, Zheng L-Y, Xia Z-F, Yao Y-M. Advances in Immune Monitoring Approaches
353 for Sepsis-Induced Immunosuppression. *Front Immunol* (2022) 13: doi:
354 10.3389/fimmu.2022.891024
- 355 16. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard A-L, Thizy H, Bienvenu J,
356 Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression
357 predicts mortality in septic shock. *Intensive Care Med* (2006) 32:1175–1183. doi:
358 10.1007/s00134-006-0204-8
- 359 17. Zorio V, Venet F, Delwarde B, Floccard B, Marcotte G, Textoris J, Monneret G, Rimmelé T.
360 Assessment of sepsis-induced immunosuppression at ICU discharge and 6 months after ICU
361 discharge. *Annals of Intensive Care* (2017) 7:80. doi: 10.1186/s13613-017-0304-3
- 362 18. Yang H, Yu Y, Chai J, Hu S, Sheng Z, Yao Y. Low HLA-DR expression on CD14+ monocytes
363 of burn victims with sepsis, and the effect of carbachol *in vitro*. *Burns* (2008) 34:1158–1162.
364 doi: 10.1016/j.burns.2008.01.026
- 365 19. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent
366 Lymphopenia After Diagnosis of Sepsis Predicts Mortality. *Shock* (2014) 42:383. doi:
367 10.1097/SHK.0000000000000234
- 368 20. Menges T, Engel J, Welters I, Wagner R-M, Little S, Ruwoldt R, Wollbrueck M, Hempelmann
369 G. Changes in blood lymphocyte populations after multiple trauma: Association with
370 posttraumatic complications. *Critical Care Medicine* (1999) 27:733.
- 371 21. McDunn JE, Turnbull IR, Polpitiya AD, Tong A, MacMillan SK, Osborne DF, Hotchkiss RS,
372 Colonna M, Cobb JP. Splenic CD4+ T cells have a distinct transcriptional response six hours
373 after the onset of sepsis. *J Am Coll Surg* (2006) 203:365–375. doi:
374 10.1016/j.jamcollsurg.2006.05.304
- 375 22. Hotchkiss RS, Tinsley KW, Swanson PE, Schmiege RE Jr, Hui JJ, Chang KC, Osborne DF,
376 Freeman BD, Cobb JP, Buchman TG, et al. Sepsis-Induced Apoptosis Causes Progressive
377 Profound Depletion of B and CD4+ T Lymphocytes in Humans¹. *The Journal of Immunology*
378 (2001) 166:6952–6963. doi: 10.4049/jimmunol.166.11.6952

- 379 23. Pachot A, Monneret G, Voirin N, Leissner P, Venet F, Bohé J, Payen D, Bienvenu J, Mouglin B,
380 Lepape A. Longitudinal study of cytokine and immune transcription factor mRNA expression in
381 septic shock. *Clinical Immunology* (2005) 114:61–69. doi: 10.1016/j.clim.2004.08.015
- 382 24. Antonakos N, Tsaganos T, Oberle V, Tsangaris I, Lada M, Pistiki A, Machairas N, Souli M,
383 Bauer M, Giamarellos-Bourboulis EJ. Decreased cytokine production by mononuclear cells
384 after severe gram-negative infections: early clinical signs and association with final outcome.
385 *Critical Care* (2017) 21:48. doi: 10.1186/s13054-017-1625-1
- 386 25. Mazer MB, C. Caldwell C, Hanson J, Mannion D, Turnbull IR, Drewry A, Osborne D, Walton
387 A, Blood T, Moldawer LL, et al. A Whole Blood Enzyme-Linked Immunospot Assay for
388 Functional Immune Endotyping of Septic Patients. *The Journal of Immunology* (2021) 206:23–
389 36. doi: 10.4049/jimmunol.2001088
- 390 26. Stein DS, Korvick JA, Vermund SH. CD4+ Lymphocyte Cell Enumeration for Prediction of
391 Clinical Course of Human Immunodeficiency Virus Disease: A Review. *The Journal of*
392 *Infectious Diseases* (1992) 165:352–363. doi: 10.1093/infdis/165.2.352
- 393 27. Margolick JB, Gange SJ, Detels R, O’Gorman MRG, Rinaldo CRJ, Lai S. Impact of Inversion
394 of the CD4/CD8 Ratio on the Natural History of HIV-1 Infection. *JAIDS Journal of Acquired*
395 *Immune Deficiency Syndromes* (2006) 42:620. doi: 10.1097/01.qai.0000223028.55080.9d
- 396 28. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, Lobashevsky A, Redfield
397 R, Schweitzer E, Heredia A, et al. Immune cell function testing: an adjunct to therapeutic drug
398 monitoring in transplant patient management. *Clinical Transplantation* (2003) 17:77–88. doi:
399 10.1034/j.1399-0012.2003.00013.x
- 400 29. Mouton W, Oriol G, Compagnon C, Saade C, Saker K, Franc P, Mokdad B, Fleurie A, Lacoux
401 X, Daniel S, et al. Combining SARS-CoV-2 interferon-gamma release assay with humoral
402 response assessment to define immune memory profiles. *Eur J Immunol* (2024) doi:
403 10.1002/eji.202451035
- 404 30. Ortiz-Brizuela E, Apriani L, Mukherjee T, Lachapelle-Chisholm S, Miedy M, Lan Z,
405 Korobitsyn A, Ismail N, Menzies D. Assessing the Diagnostic Performance of New Commercial
406 Interferon- γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review
407 and Meta-Analysis. *Clin Infect Dis* (2023) 76:1989–1999. doi: 10.1093/cid/ciad030

408

409 **7 Author Contributions**

410 All authors were involved in the analysis and interpretation of data, as well as drafting the manuscript
411 or revising it critically for important intellectual content. MD, STA and WM made substantial
412 contributions to the conception and design of the study and designed the experiments. MD and WM
413 performed the experiments. MD, GO, CD, and WM performed the data analyses. MD, WM and STA
414 drafted the manuscript. All authors read and approved the final manuscript. WM and STA take
415 responsibility for the integrity of the data analysis.

416 **8 Conflict of Interest**

417 MD, GO, KBP and AF are employed by the in-vitro diagnostic company bioMérieux.

418 **9 Funding**

419 *REALISM study* - This work was supported by the French National Research Agency through a grant
420 awarded to BIOASTER (Grant number #ANR-10-AIRT-03) and from bioMérieux, Sanofi and GSK.

421 *VaccHemInf – FIGHT study* – This work was supported by an internal grant from the *Hospices Civils*
422 *de Lyon* (Appel d'Offre Jeune Chercheur 2018, to A.C.); the *Région Auvergne-Rhône-Alpes* (Pack
423 Ambition Recherche 2019, to F.A.)

424 This work was supported by the public grant overseen by the French National Research Agency
425 (*Chaires industrielles 2023*) and supported by the *Association Nationale de la Recherche et de la*
426 *Technologie* (ANRT) with a CIFRE fellowship granted to Marion Debombourg.

427 **10 Acknowledgments**

428 The authors thank Jonathan Lopez, Pauline Berlier and Isabelle Mosnier for their technical assistance
429 on Nanostring molecular biology; Verena Landel for language editing and critical reading of the
430 manuscript.

431

FIGURE 1






FIGURE 2**A.**

Overlay of stimulated and unstimulated dataset

**B.****C.**